USD10
BEAM Shares
About Beam TherapeuticsBeam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
USD10
BEAM Shares
About Beam TherapeuticsBeam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
Stats
TRADING WINDOW
Closed
OPENS AT
Mar 26 at 1:30 PM GMT+0
MARKET CAP
$2.42B
OPEN PRICE
$23.15
LOW (1Y)
$13.53
HIGH (1Y)
$36.44
LOW (24H)
$22.76
HIGH (24H)
$24.59
VOLUME (24H)
$2.30M
56.93%
Price history
Time | Price | Change |
|---|---|---|
Today | $23.15 | |
1 Day | $23.75 | |
1 Week | $25.17 | |
1 Month | $29.28 | |
1 Year | $22.19 |